Breaking News Instant updates and real-time market news.

SNNA

Sienna Biopharmaceuticals

$1.43

-0.13 (-8.33%)

09:16
05/14/19
05/14
09:16
05/14/19
09:16

Sienna Biopharmaceuticals announces biopsy data from Phase 2b SNA-120 trial

Sienna Biopharmaceuticals announced biopsy data from its recent Phase 2b clinical trial with SNA-120, the company's Phase 3 topical, non-steroidal Tropomyosin receptor kinase A, or TrkA, inhibitor under investigation for the treatment of psoriasis. Biopsy analyses were conducted at The Rockefeller University on 22 subjects, and included immunohistochemistry, or IHC, MicroArray and quantitative Reverse Transcription Polymerase Chain Reaction, or qRT-PCR. Specifically, the immunohistochemistry analysis showed meaningful and statistically significant improvement in the epidermal thickness at Week 12, supporting the effect of SNA-120 on keratinocyte hyperproliferation and inflammation. In addition, the data demonstrated a statistically significant reduction in T cell and dendritic cell counts, confirming an immune response to treatment with SNA-120. In MicroArray analyses, SNA-120 was also observed to affect most of the key inflammatory pathways in psoriasis in a statistically significant manner when compared to vehicle at Week 12. In the qRT-PCR analysis, SNA-120 demonstrated substantial, statistically significant gene expression improvements in key cytokines that play an important role in psoriasis pathogenesis, including IL-23, IL-12, IL-17A and IFNg, among other cytokines, in PASI 75 responders and even led to restoration to non-lesional expression levels, further validating the strong pharmacological effect of SNA-120.

  • 30

    May

SNNA Sienna Biopharmaceuticals
$1.43

-0.13 (-8.33%)

07/31/18
BMOC
07/31/18
NO CHANGE
Target $27
BMOC
Outperform
Sienna has bigger value drivers than SNA-001 in acne, says BMO Capital
BMO Capital analyst Gary Nachman called Sienna Biopharmaceuticals' announcement that SNA-001 failed in two of its three pivotal studies in acne an "unfortunate outcome," but he believes the bigger long-term value drivers for Sienna remain SNA-001 for light-hair removal and SNA-125 for psoriasis and atopic dermatitis. After removing any SNA-001 acne revenue from his estimates, Nachman lowered his price target on Sienna Biopharmaceuticals to $27 from $30 and keeps an Outperform rating on the shares.
10/10/18
BMOC
10/10/18
NO CHANGE
BMOC
BMO Capital confident in management, pipeline at Sienna Biopharmaceuticals
BMO Capital analyst Gary Nachman reiterated an Outperform rating on Sienna Biopharmaceuticals shares after recent investor meetings with management. The analyst is "cautiously optimistic" on SNA-001 in hair removal, sees good risk/reward for SNA-120 in pruritis associated with psoriasis and SNA-125 for atopic dermatitis, and over is "confident in management's ability to execute this pipeline with multiple shots on goal."
12/04/18
BMOC
12/04/18
NO CHANGE
Target $17
BMOC
Outperform
Sienna Biopharmaceuticals price target lowered to $17 from $27 at BMO Capital
BMO Capital analyst Gary Nachman lowered his price target on Sienna Biopharmaceuticals to $17 following its mixed Phase 2b results for SNA-120. The analyst states that the program missed the primary endpoint in pruritis, but showed surprisingly good results on key secondary endpoints in psoriasis and sees the management changing its course to focus on the psoriasis indication. Nachman keeps his Outperform rating on Sienna Biopharmaceuticals based on the potential of SNA-120 in psoriasis, even though he acknowledges its "increased development risk and questions regarding ultimate opportunity in a crowded psoriasis market".
05/13/19
JPMS
05/13/19
DOWNGRADE
JPMS
Neutral
Sienna Biopharmaceuticals downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chris Schott downgraded Sienna Biopharmaceuticals to Neutral from Overweight without a price target. While the analyst continues to see SNA-120 and SNA-125 as "interesting assets," he sees few near-term catalysts in the story with data not expected until 2020 and beyond.

TODAY'S FREE FLY STORIES

02:10
05/21/19
05/21
02:10
05/21/19
02:10
General news
Asian Market Wrap: »

Asian Market Wrap:…

OXY

Occidental Petroleum

$53.49

0.74 (1.40%)

21:25
05/20/19
05/20
21:25
05/20/19
21:25
Downgrade
Occidental Petroleum rating change at Wells Fargo »

Occidental Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

TIGR

UP Fintech

$5.63

-0.14 (-2.43%)

20:41
05/20/19
05/20
20:41
05/20/19
20:41
Hot Stocks
Interactive Brokers Group discloses 7.6% stake in UP Fintech »

IBGI acquired beneficial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TJX

TJX

$52.95

-0.08 (-0.15%)

, HD

Home Depot

$190.87

-1.66 (-0.86%)

20:25
05/20/19
05/20
20:25
05/20/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TJX

TJX

$52.95

-0.08 (-0.15%)

HD

Home Depot

$190.87

-1.66 (-0.86%)

AZO

AutoZone

$978.78

-5.21 (-0.53%)

KSS

Kohl's

$62.95

-0.68 (-1.07%)

EV

Eaton Vance

$37.27

-0.535 (-1.42%)

JCP

J.C. Penney

$1.15

0.01 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 23

    May

  • 24

    May

  • 29

    May

  • 04

    Jun

  • 11

    Jun

JCOM

j2 Global

$86.48

-0.23 (-0.27%)

20:22
05/20/19
05/20
20:22
05/20/19
20:22
Hot Stocks
j2 Global CFO sells 10K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 05

    Jun

ATTO

Atento

$3.24

-0.14 (-4.14%)

19:58
05/20/19
05/20
19:58
05/20/19
19:58
Earnings
Atento sees FY19 revenue flat to up single digits »

The company sees sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

ATTO

Atento

$3.24

-0.14 (-4.14%)

19:57
05/20/19
05/20
19:57
05/20/19
19:57
Earnings
Atento reports Q1 recurring EPS (6c), consensus 10c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

ITCB

Itau Corpbanca

$12.95

(0.00%)

19:38
05/20/19
05/20
19:38
05/20/19
19:38
Hot Stocks
Itau Corpbanca dissolves subsidiary Corplegal »

Itau Corpbanca announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCUL

Ocular Therapeutix

$3.36

-0.1 (-2.89%)

19:36
05/20/19
05/20
19:36
05/20/19
19:36
Recommendations
Ocular Therapeutix analyst commentary at Piper Jaffray »

Ocular Therapeutix price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 10

    Nov

YGYI

Youngevity

$6.57

0.13 (2.02%)

, QFIN

360 Finance

$16.46

0.71 (4.51%)

18:55
05/20/19
05/20
18:55
05/20/19
18:55
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

YGYI

Youngevity

$6.57

0.13 (2.02%)

QFIN

360 Finance

$16.46

0.71 (4.51%)

ARWR

Arrowhead

$18.94

-0.52 (-2.67%)

TRIP

TripAdvisor

$44.93

-0.07 (-0.16%)

ASNA

Ascena Retail

$1.13

-0.125 (-9.96%)

KR

Kroger

$24.04

-0.18 (-0.74%)

SNAP

Snap

$11.19

-0.3 (-2.61%)

NDSN

Nordson

$130.42

-4.8 (-3.55%)

OCUL

Ocular Therapeutix

$3.36

-0.1 (-2.89%)

SWI

SolarWinds

$19.16

0.04 (0.21%)

MRCY

Mercury Systems

$72.85

-0.11 (-0.15%)

VNE

Veoneer

$18.89

0.02 (0.11%)

GH

Guardant Health

$78.29

2.13 (2.80%)

CVNA

Carvana

$67.17

-0.935 (-1.37%)

INSM

Insmed

$28.08

-1.08 (-3.70%)

VAR

Varian Medical

$130.48

-0.26 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 18

    Jun

  • 23

    Jun

  • 10

    Nov

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    Jun

TOL

Toll Brothers

$37.52

-0.88 (-2.29%)

18:47
05/20/19
05/20
18:47
05/20/19
18:47
Hot Stocks
Toll Brothers acquires Sharp Residential, terms not disclosed »

Toll Brothers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

18:45
05/20/19
05/20
18:45
05/20/19
18:45
General news
Breaking General news story  »

Federal Reserve Chairman…

TTWO

Take-Two

$102.94

-3.82 (-3.58%)

18:44
05/20/19
05/20
18:44
05/20/19
18:44
Hot Stocks
Take-Two CEO: Our job is to excite customers »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Nov

AAL

American Airlines

$30.96

-0.8 (-2.52%)

18:40
05/20/19
05/20
18:40
05/20/19
18:40
Periodicals
American Air asks court to halt alleged mechanics unions' slowdown, Reuters says »

American Airlines has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 29

    May

  • 12

    Jun

  • 12

    Jun

LWAY

Lifeway Foods

$2.75

0.05 (1.85%)

18:38
05/20/19
05/20
18:38
05/20/19
18:38
Earnings
Lifeway Foods reports Q1 EPS (2c) vs. 0c last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

WHLR

Wheeler REIT

$2.25

0.025 (1.13%)

18:31
05/20/19
05/20
18:31
05/20/19
18:31
Hot Stocks
Wheeler REIT chairman John Sweet to resign »

Wheeler Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$101.54

0.66 (0.65%)

, TGT

Target

$72.10

1.22 (1.72%)

18:03
05/20/19
05/20
18:03
05/20/19
18:03
Periodicals
Judge says Walmart, Target, Bed Bath must face suits over cotton, Reuters says »

U.S. District Judge…

WMT

Walmart

$101.54

0.66 (0.65%)

TGT

Target

$72.10

1.22 (1.72%)

BBBY

Bed Bath & Beyond

$14.48

-0.525 (-3.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 22

    May

  • 29

    May

  • 05

    Jun

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 12

    Jun

  • 15

    Aug

  • 13

    Nov

QFIN

360 Finance

$16.46

0.71 (4.51%)

18:02
05/20/19
05/20
18:02
05/20/19
18:02
Earnings
360 Finance reports Q1 net income $117.5M, up 382% from last year »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

MRK

Merck

$78.86

0.15 (0.19%)

18:02
05/20/19
05/20
18:02
05/20/19
18:02
Hot Stocks
Merck falls after Keytruda trial does not meet OS primary endpoint »

Shares of Merck have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 20

    Sep

PRIM

Primoris

$20.26

-0.08 (-0.39%)

17:55
05/20/19
05/20
17:55
05/20/19
17:55
Hot Stocks
Primoris director sells 99.8K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$45.97

-0.11 (-0.24%)

, LM

Legg Mason

$35.68

0.295 (0.83%)

17:44
05/20/19
05/20
17:44
05/20/19
17:44
Hot Stocks
BNY Mellon announces Ed Garden to step down from board of directors »

BNY Mellon (BK) announced…

BK

BNY Mellon

$45.97

-0.11 (-0.24%)

LM

Legg Mason

$35.68

0.295 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

DHR

Danaher

$130.33

-0.81 (-0.62%)

17:44
05/20/19
05/20
17:44
05/20/19
17:44
Hot Stocks
VP of Danaher Angela Lalor sells over $408K in company shares »

VP of Danaher Angela…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 07

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$283.95

-2.03 (-0.71%)

17:43
05/20/19
05/20
17:43
05/20/19
17:43
Periodicals
Judge dismisses Trump request to block accounting subpoena, WSJ says »

U.S. District Judge Amit…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$283.95

-2.03 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LM

Legg Mason

$35.68

0.295 (0.83%)

17:40
05/20/19
05/20
17:40
05/20/19
17:40
Hot Stocks
Legg Mason names Nelson Peltz, Ed Garden to board of directors »

Legg Mason announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XYF

X Financial

$5.42

0.1 (1.88%)

17:34
05/20/19
05/20
17:34
05/20/19
17:34
Earnings
X Financial reports Q1 EPS 24c, consensus 24c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.